These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1001 related items for PubMed ID: 8542938

  • 1. Hematopoietic growth factors after HLA-identical allogeneic bone marrow transplantation in patients treated with methotrexate-containing graft-vs.-host disease prophylaxis.
    Martin-Algarra S, Bishop MR, Tarantolo S, Cowles MK, Reed E, Anderson JR, Vose JM, Bierman P, Armitage JO, Kessinger A.
    Exp Hematol; 1995 Dec; 23(14):1503-8. PubMed ID: 8542938
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Allogeneic peripheral blood stem cell transplantation in patients with early-phase hematologic malignancy: a retrospective comparison of short-term outcome with bone marrow transplantation.
    Lemoli RM, Bandini G, Leopardi G, Rosti G, Bonini A, Fortuna A, Rondelli D, Mangianti S, Motta MR, Rizzi S, Tassi C, Cavo M, Remiddi C, Curti A, Conte R, Tura S.
    Haematologica; 1998 Jan; 83(1):48-55. PubMed ID: 9542323
    [Abstract] [Full Text] [Related]

  • 4. Different response to recombinant human granulocyte-macrophage colony-stimulating factor in primary and secondary graft failure after bone marrow transplantation.
    Sierra J, Terol MJ, Urbano-Ispizua A, Rovira M, Marin P, Carreras E, Batlle M, Rozman C.
    Exp Hematol; 1994 Jul; 22(7):566-72. PubMed ID: 8013572
    [Abstract] [Full Text] [Related]

  • 5. Recombinant human granulocyte-macrophage colony-stimulating factor accelerates engraftment kinetics after allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia.
    Madero L, Díaz MA, Ortega JJ, Olive T, Martínez A, Badell I, Muñoz A, Gómez P.
    Haematologica; 1999 Feb; 84(2):133-7. PubMed ID: 10091411
    [Abstract] [Full Text] [Related]

  • 6. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Ringdén O, Labopin M, Gorin NC, Le Blanc K, Rocha V, Gluckman E, Reiffers J, Arcese W, Vossen JM, Jouet JP, Cordonnier C, Frassoni F.
    J Clin Oncol; 2004 Feb 01; 22(3):416-23. PubMed ID: 14691124
    [Abstract] [Full Text] [Related]

  • 7. Unrelated donor bone marrow transplantation without T cell depletion using a chemotherapy only condition regimen. Low incidence of failed engraftment and severe acute GVHD.
    Topolsky D, Crilley P, Styler MJ, Bulova S, Brodsky I, Marks DI.
    Bone Marrow Transplant; 1996 Apr 01; 17(4):549-54. PubMed ID: 8722353
    [Abstract] [Full Text] [Related]

  • 8. Allogeneic peripheral blood progenitor cell transplantation: analysis of short-term engraftment and acute GVHD incidence in 33 cases. allo-PBPCT Spanish Group.
    Urbano-Ispizua A, Solano C, Brunet S, Hernández F, Sanz G, Alegre A, Petit J, Besalduch J, Vivancos P, Díaz MA, Moraleda JM, Carreras E, Ojeda E, de la Rubia J, Benet I, Domingo-Albós A, García-Conde J, Rozman C.
    Bone Marrow Transplant; 1996 Jul 01; 18(1):35-40. PubMed ID: 8831993
    [Abstract] [Full Text] [Related]

  • 9. Phase III randomized, double-blind placebo-controlled trial of rhGM-CSF following allogeneic bone marrow transplantation.
    Nemunaitis J, Rosenfeld CS, Ash R, Freedman MH, Deeg HJ, Appelbaum F, Singer JW, Flomenberg N, Dalton W, Elfenbein GJ.
    Bone Marrow Transplant; 1995 Jun 01; 15(6):949-54. PubMed ID: 7581096
    [Abstract] [Full Text] [Related]

  • 10. Factors influencing the haematological recovery after allogeneic bone marrow transplantation in leukaemia patients treated with methotrexate-containing GVHD prophylaxis: a single-centre experience.
    Hassan HT, Krog C, Stockschläder M, Schleimer B, Zeller W, Krüger W, Erttmann R, Zander AR.
    Anticancer Res; 1997 Jun 01; 17(1B):589-99. PubMed ID: 9066585
    [Abstract] [Full Text] [Related]

  • 11. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
    Soiffer RJ, Mauch P, Fairclough D, Alyea E, Anderson K, Fisher D, Freedman A, Bartlett-Pandite L, Robertson M, Schlossman R, Gollob J, Marcus K, Murray C, Kuhlman C, Freeman A, Nadler L, Ritz J.
    Biol Blood Marrow Transplant; 1997 Apr 01; 3(1):11-7. PubMed ID: 9209736
    [Abstract] [Full Text] [Related]

  • 12. Prognostic factors for long-term survival in leukemic marrow recipients with special emphasis on age and prophylaxis for graft-versus-host disease.
    Aschan J, Ringdén O.
    Clin Transplant; 1994 Jun 01; 8(3 Pt 1):258-70. PubMed ID: 8061365
    [Abstract] [Full Text] [Related]

  • 13. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
    Mengarelli A, Iori A, Guglielmi C, Romano A, Cerretti R, Torromeo C, Micozzi A, Fenu S, Laurenti L, Donato V, De Felice L, Arcese W.
    Haematologica; 2002 Jan 01; 87(1):52-8. PubMed ID: 11801465
    [Abstract] [Full Text] [Related]

  • 14. Recombinant human granulocyte colony-stimulating factor (rh-G-CSF) may accelerate hematopoietic recovery after HLA-identical sibling allogeneic peripheral blood stem cell transplantation.
    Ozcan M, Ustün C, Akçağlayan E, Akan H, Arslan O, Ilhan O, Beksaç M, Gürman G, Demirer T, Arat M, Celebi H, Konuk N, Uysal A, Koç H.
    Bone Marrow Transplant; 2001 Mar 01; 27(5):499-505. PubMed ID: 11313683
    [Abstract] [Full Text] [Related]

  • 15. Recombinant human granulocyte colony-stimulating factor after allogeneic bone marrow transplantation.
    Huang X, Guo N, Fan Y, Lu D.
    Chin Med J (Engl); 1996 Nov 01; 109(11):827-31. PubMed ID: 9275365
    [Abstract] [Full Text] [Related]

  • 16. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies.
    Chen XH, Zhang C, Zhang X, Gao L, Gao L, Kong PY, Peng XG, Qi DG, Sun AH, Zeng DF, Liu H, Gong Y, Wang QY.
    Biol Blood Marrow Transplant; 2009 Feb 01; 15(2):266-73. PubMed ID: 19167687
    [Abstract] [Full Text] [Related]

  • 17. The outcome of unrelated donor bone marrow transplantation in patients with hematologic malignancies using tacrolimus (FK506) and low dose methotrexate for graft-versus-host disease prophylaxis.
    Devine SM, Geller RB, Lin LB, Dix SP, Holland HK, Maurer D, O'Toole K, Keller J, Connaghan DG, Heffner LT, Hillyer CD, Rodey GE, Winton EF, Maher RM, Fitzsimmons WE, Wingard JR.
    Biol Blood Marrow Transplant; 1997 Apr 01; 3(1):25-33. PubMed ID: 9209738
    [Abstract] [Full Text] [Related]

  • 18. Methotrexate vs Cyclosporin A as a single agent for graft-versus-host disease prophylaxis in pediatric patients with hematological malignancies undergoing allogeneic bone marrow transplantation from HLA-identical siblings: a single-center analysis in Japan.
    Koga Y, Nagatoshi Y, Kawano Y, Okamura J.
    Bone Marrow Transplant; 2003 Jul 01; 32(2):171-6. PubMed ID: 12838282
    [Abstract] [Full Text] [Related]

  • 19. A pilot study of allogeneic bone marrow transplantation using related donors stimulated with G-CSF.
    Isola LM, Scigliano E, Skerrett D, Shank B, Ross V, Najfeld V, Fruchtman S.
    Bone Marrow Transplant; 1997 Dec 01; 20(12):1033-7. PubMed ID: 9466275
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 51.